The findings illustrate the potential for a new era of genomic medicine, in which drug regimens are tailored to fit a person's genetic risk factors.

FORBES: Quelling An Inflamed Heart

To identify gene function, drug companies are forming partnerships with genomic startup firms.

FORBES: A hail of silver bullets

Their hopes that genomic information and other new tools would dramatically improve drug making are justified, but certainly not as fast or as cheaply as they once expected.

ECONOMIST: Pharmaceuticals

"This is the first new drug-development platform in the post-genomic era, " beams Lanphier.

FORBES: Magazine Article

Big data and analytics are playing indispensable roles in fostering those enhanced relationships as they vastly enrich the remarkable but isolated wonder of genome-on-a-thumb-drive by giving healthcare providers and drug makers the ability to explore and analyze genomic and proteomic data not just for an individual but in aggregate for millions of people.

FORBES: Big Data Gets Personal as Healthcare and Life Sciences Converge